Biodegradable Cisplatin Polymer in Limb-Sparing Surgery for Canine Osteosarcoma

Withrow, Stephen J.; Liptak, Julius M.; Straw, Rodney C.; Dernell, William S.; Jameson, Vicki J.; Powers, Barbara E.; Johnson, Jeffery L.; Brekke, John H.; Douple, Evan B.

doi:10.1245/aso.2004.10.008

Cited by 75 publications

(88 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…309 However, unlike amputation, marginal resection of the primary tumor in limb sparing techniques can result in the rate of local recurrence to be as high as 28%. 310 Therefore, biodegradable bone scaffolds capable of sustained and controlled drug elution are ideal candidates for limb sparing treatments in osteosarcoma patients. One group recently investigated an open cell polylactic acid scaffold containing 8 wt % cisplatin (platinum-based chemotherapeutic) in an animal model.…”

Section: Antibiotics and Chemotherapeuticsmentioning

confidence: 99%

Bone tissue engineering: A review in bone biomimetics and drug delivery strategies

Porter

Ruckh

Popat

2009

Biotechnology Progress

685

499

View full text Add to dashboard Cite

Critical‐sized defects in bone, whether induced by primary tumor resection, trauma, or selective surgery have in many cases presented insurmountable challenges to the current gold standard treatment for bone repair. The primary purpose of a tissue‐engineered scaffold is to use engineering principles to incite and promote the natural healing process of bone which does not occur in critical‐sized defects. A synthetic bone scaffold must be biocompatible, biodegradable to allow native tissue integration, and mimic the multidimensional hierarchical structure of native bone. In addition to being physically and chemically biomimetic, an ideal scaffold is capable of eluting bioactive molecules (e.g., BMPs, TGF‐βs, etc., to accelerate extracellular matrix production and tissue integration) or drugs (e.g., antibiotics, cisplatin, etc., to prevent undesired biological response such as sepsis or cancer recurrence) in a temporally and spatially controlled manner. Various biomaterials including ceramics, metals, polymers, and composites have been investigated for their potential as bone scaffold materials. However, due to their tunable physiochemical properties, biocompatibility, and controllable biodegradability, polymers have emerged as the principal material in bone tissue engineering. This article briefly reviews the physiological and anatomical characteristics of native bone, describes key technologies in mimicking the physical and chemical environment of bone using synthetic materials, and provides an overview of local drug delivery as it pertains to bone tissue engineering is included. © 2009 American Institute of Chemical Engineers Biotechnol. Prog., 2009

show abstract

Section: Antibiotics and Chemotherapeuticsmentioning

confidence: 99%

Bone tissue engineering: A review in bone biomimetics and drug delivery strategies

Porter

Ruckh

Popat

2009

Biotechnology Progress

685

499

View full text Add to dashboard Cite

show abstract

“…Use of locally delivered chemotherapy has been explored extensively for dogs with naturally occurring canine tumors (2, 3, 6, 23–25). Wound implantation of cisplatin-impregnated open-cell polylactic acid (OPLA-Pt) was shown to be tolerated and effective against metastasis and local recurrence in dogs receiving limb-sparing surgery (2, 6, 23–25).…”

Section: Discussionmentioning

confidence: 99%

“…Wound implantation of cisplatin-impregnated open-cell polylactic acid (OPLA-Pt) was shown to be tolerated and effective against metastasis and local recurrence in dogs receiving limb-sparing surgery (2, 6, 23–25). Following wound implantation of either 82 or 54 mg/m 2 OPLA-Pt, the combined mean area under the curve for total serum platinum concentration was almost 30 times greater than that after a single i.v.…”

Section: Discussionmentioning

confidence: 99%

Docetaxel Accumulates in Lymphatic Circulation Following Subcutaneous Delivery Compared to Intravenous Delivery in Rats

Worley

Hansen

Wittenburg

et al. 2016

View full text Add to dashboard Cite

Background The circulatory pathway for particles deposited outside of blood capillaries has not been well characterized for non-traditionally-delivered chemotherapeutics. Materials and Methods Blood and lymph pharmacokinetics of docetaxel (5 mg/kg) and carboplatin (14 and 28 mg/kg) following subcutaneous (s.c.) versus intravenous (i.v.) delivery were determined in a rodent model with catheterizations of both the thoracic lymphatic duct and jugular vein for prolonged synchronous blood and lymph sampling. Results Subcutaneous docetaxel demonstrates preferential lymphatic accumulation based on the area under the time-concentration curve (AUC0–24h) whereas i.v. docetaxel resulted in a greater plasma maximum concentration measured (Cmax). The apparent elimination half-life (t1/2) in lymph for docetaxel is greater following i.v. or s.c. delivery as compared to t1/2 in blood. Carboplatin demonstrates a dose-dependent increase in plasma Cmax regardless of delivery route; the total carboplatin exposure over 24 hours in lymph and plasma are comparable. Conclusion Subcutaneous docetaxel achieves lymphatic accumulation greater than with i.v. delivery.

show abstract

“…Other investigators have reported nephrotoxicosis in up to 73% of dogs undergoing cisplatin therapy. 10 However, different protocols, dosing regimens, and definitions of nephrotoxicosis make it difficult to compare the frequency of this adverse effect. Similar to these results, approximately one third of people treated with cisplatin chemotherapy have irreversible renal damage.…”

Section: Discussionmentioning

confidence: 99%

Microalbuminuria Is Not Associated with Cisplatin‐Induced Azotemia in Dogs

Autio

Rassnick

Goldstein

et al. 2007

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background: Cisplatin is an effective antineoplastic agent but its use is limited by renal toxicity. Microalbuminuria is a marker of renal damage and might be an indicator of cisplatin-induced azotemia.Null Hypothesis: Microalbuminuria is not associated with azotemia in dogs treated with cisplatin. Animals: This study used 32 client-owned dogs.Methods: This was a prospective observational study in which cancer-bearing dogs were treated with cisplatin chemotherapy. Cisplatin-induced azotemia was defined as an increase of serum creatinine concentration above the reference range. Serum creatinine concentration, other routine tests of renal function, and microalbuminuria were measured after each cisplatin treatment. Variables potentially associated with azotemia were compared by use of Fisher's exact test and Wilcoxon's rank-sum test.Results: Cisplatin-induced azotemia occurred in 10 (31%) dogs after 1-5 treatments. At each of the first 3 treatments, the proportions of dogs with microalbuminuria were similar between dogs with and without azotemia.Conclusions and Clinical Importance: Microalbuminuria measured after each treatment was not associated with azotemia through the first 3 treatments. Testing for microalbuminuria as a marker for cisplatin-induced renal damage is insensitive and not recommended.

show abstract

Biodegradable Cisplatin Polymer in Limb-Sparing Surgery for Canine Osteosarcoma

Abstract: Local tumor recurrence may be decreased after limb-sparing surgery by use of biodegradable implants impregnated with chemotherapeutic agents.

Cited by 75 publications

References 34 publications

Bone tissue engineering: A review in bone biomimetics and drug delivery strategies

Bone tissue engineering: A review in bone biomimetics and drug delivery strategies

Docetaxel Accumulates in Lymphatic Circulation Following Subcutaneous Delivery Compared to Intravenous Delivery in Rats

Microalbuminuria Is Not Associated with Cisplatin‐Induced Azotemia in Dogs

Contact Info

Product

Resources

About